A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jie Yang
- 전화번호: +8621-58372390
- 이메일: yangj@longbiopharma.com
연구 장소
-
-
-
Beijing, 중국
- Peking Union Medical College Hospital
-
연락하다:
- Yuxiang Zhi
- 전화번호: +8610-69151188
- 이메일: yuxiang_zhi@126.com
-
Shenyang, 중국
- The First Affiliated Hospital of China Medical University
-
연락하다:
- Xinghua Gao
- 전화번호: +8624-83282524
- 이메일: Gaobarry@hotmail.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
- Male or female participant must be 12 to 75 years old at the time of ICF signature;
- Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
- Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
- Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
- Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
- Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.
Exclusion Criteria:
- The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
- Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
- Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
- Body weight < 40 kg
- Not enough washing-out period for previous therapy before randomization.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: LP-003 group
Participants received LP-003 subcutaneously during the 48-week treatment period |
s.c. injection |
|
활성 비교기: Omalizumab group
Participants received omalizumab subcutaneously during the 48-week treatment period |
s.c. injection |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
기간: Week 12
|
The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria. |
Week 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
기간: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 = 0 at each assessment visit
기간: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 ≤ 6at each assessment visit
기간: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
기간: up to approximately 56 weeks
|
The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives. |
up to approximately 56 weeks
|
|
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
기간: Time Frame: up to approximately 56 weeks
|
The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
기간: Time Frame: up to approximately 56 weeks
|
The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
기간: up to approximately 56 weeks
|
The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life |
up to approximately 56 weeks
|
|
The incidence of adverse events during the study
기간: up to approximately 56 weeks
|
Incidence and severity of AE from first dose to end of study are recorded |
up to approximately 56 weeks
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Xinghua Gao, First Hospital of China Medical University
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- P10-LP003-14
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .